Agile Therapeutics, Inc.
101 Poor Farm Road
Princeton
New Jersey
08540
United States
Tel: 609-683-1880
Fax: 609-683-1855
Website: http://www.agiletherapeutics.com/
Email: info@agiletherapeutics.com
248 articles about Agile Therapeutics, Inc.
-
Agile Therapeutics to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Wednesday, March 30, 2022Live Conference Call and Webcast at 4:30 p.m. ET
3/7/2022
Agile Therapeutics, Inc. today announced it will report fourth quarter and full year 2021 financial results after the market close on Wednesday, March 30, 2022.
-
Agile Therapeutics and Afaxys Partner to Expand Access to Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System
1/10/2022
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced a new alliance with Afaxys Pharma, LLC to promote Twirla® (levonorgestrel and ethinyl estradiol) transdermal system.
-
Agile Therapeutics to Present at the Biotech Showcase and H.C. Wainwright BioConnect Virtual Conferences
1/5/2022
Agile Therapeutics, Inc., a women's healthcare company, announced Chairman and Chief Executive Officer Al Altomari will present at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022, and at Biotech Showcase taking place January 10-12, 2022.
-
Agile Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 7:30 a.m. ET.
-
Agile Therapeutics Reports Third Quarter 2021 Financial Results
11/2/2021
Agile Therapeutics, Inc., a women's healthcare company, reported financial results for the three months ended September 30, 2021 and provided a corporate update.
-
Agile Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on Tuesday, November 2, 2021Live Conference Call and Webcast at 4:30 p.m. ET
10/22/2021
Agile Therapeutics, Inc. today announced it will report third quarter 2021 financial results after the market close on Tuesday, November 2, 2021
-
Agile Therapeutics Appoints Josephine Torrente to its Board of Directors
10/8/2021
Agile Therapeutics, Inc., a women’s healthcare company, announced that Josephine Torrente has been appointed to the Company’s board of directors, as a Class II director, effective as of October 7, 2021.
-
Agile Therapeutics Announces Pricing of $22,666,650 Underwritten Public Offering of Common Stock and Warrants
10/8/2021
Agile Therapeutics, Inc. today announced the pricing of its underwritten public offering of 26,666,648 shares of its common stock and warrants to purchase 13,333,324 shares of its common stock at a combined offering price to the public of $0.85 per one share of common stock and one-half of a warrant to purchase one share of common stock.
-
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Warrants - Oct 07, 2021
10/7/2021
Agile Therapeutics, Inc., a women’s healthcare company, announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.
-
Agile Therapeutics Announces Addition of Twirla® to a Preferred Drug Position on Medi-Cal FormularyLargest Medicaid program in the U.S. adds Twirla to Preferred Drug List as of October 1, 2021
10/4/2021
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that the California Medicaid Program, Medi-Cal, has placed Twirla on the preferred drug formulary list as of October 1, 2021.
-
Agile Therapeutics to Participate in Upcoming Investor Conferences
9/7/2021
Agile Therapeutics, Inc. today announced that management will present and participate at the following virtual investor conferences during the month of September 2021.
-
Agile Therapeutics Partners with Telehealth Service, Pandia Health, to Increase Women’s Access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system
8/20/2021
Agile Therapeutics, Inc. today announced a partnership with Pandia Health, an online telehealth service, which will establish the first telehealth relationship for Agile and offer an additional point of access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system in a fast-growing channel.
-
Agile Therapeutics Reports Second Quarter 2021 Financial Results
7/26/2021
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three months ended June 30, 2021 and provided a corporate update.
-
Agile Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on Monday, July 26, 2021Live Conference Call and Webcast at 4:30 p.m. EDT
7/1/2021
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report second quarter 2021 financial results after the market close on Monday, July 26, 2021
-
Agile Therapeutics to Participate in the William Blair 41st Annual Growth Stock Conference
5/26/2021
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the company will be participating virtually in the William Blair 41st Annual Growth Stock Conference.
-
Agile Therapeutics to Participate in Virtual Fireside Chat as Part of the 2021 RBC Capital Markets Global Healthcare Conference
5/12/2021
Agile Therapeutics, Inc., a women’s healthcare company, announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat as part of the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 1:20 p.m. ET.
-
Agile Therapeutics Reports First Quarter 2021 Financial Results
5/4/2021
Agile Therapeutics, Inc., a women's healthcare company, reported financial results for the three months ended March 31, 2021 and provided a corporate update.
-
Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women of Differing BMI Categories at ACOG Annual Meeting
4/30/2021
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial evaluating the safety and efficacy of Twirla ® (levonorgestrel and ethinyl estradiol) transdermal system in women with BMI < 25 kg/m 2 and women with BMI 25-30 kg/m 2 will be presented at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting from April 30-May 2
-
CORRECTING AND REPLACING -- Agile Therapeutics
4/20/2021
In a release issued earlier today by Agile Therapeutics, Inc. (Nasdaq: AGRX), please note the headline should read "Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2021" instead of "Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2020". The corrected release follows: Agile Therapeutics to Report First Quarter 2021
-
Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2020Live Conference Call and Webcast at 4:30 p.m. EDT
4/20/2021
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report first quarter 2021 financial results after the market close on Tuesday, May 4, 2021